TapewireFind a company

person · Reporting owner

Schuth Alexander O.

Disclosed activity across 1 company

Tapewire entity
1736
SEC CIK
0001724311

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Denali Therapeutics Inc.DNLI · Entity 1735COFO and SecretarySeptember 01, 2026September 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Denali Therapeutics Inc.

Report date September 01, 2026 · Filed September 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect278,995 Reported balance After 2026-09-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-01 · Sale · Disposed 2,768 · Balance 278,995

F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.

F2: Includes 135,475 Unvested RSUs.

Common StockSEC Table I · non-derivativeIndirectSee footnote523,749 Reported balance Holding disclosure · report date 2026-09-01 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 523,749

F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.

F2: Includes 135,475 Unvested RSUs.

F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 01, 2026 Filed Sep 3, 2026 20:17 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,768 $23.44 $64,881.92
Disclosure

SEC source: 0001724311-26-000014 · wk-form4_1788466654.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 278,995

F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2026.

F2 · balance_after: Includes 135,475 Unvested RSUs.

Read SEC document
August 11, 2026 Filed Aug 13, 2026 21:01 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,857 $25.07 $71,624.99
Disclosure

SEC source: 0001724311-26-000013 · wk-form4_1786654917.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,763

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.

F2 · balance_after: Includes 135,475 Unvested RSUs.

F3 · balance_after: Includes 1,792 shares acquired under the ESPP Purchase on June 1, 2026.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 21:19 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 17,218 $16.50 $284,097.00
Disclosure

SEC source: 0001724311-26-000005 · wk-form4_1767907181.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,828

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested RSUs.

F2 · balance_after: Includes 141,100 Unvested RSUs.

Read SEC document
January 03, 2026 Filed Jan 5, 2026 23:49 UTC Denali Therapeutics Inc. DNLI · Entity 1735 GrantStock Option (right to buy) · Derivative 173,100 $0.00 Strike: $16.27 $0.00
Disclosure

SEC source: 0001724311-26-000001 · wk-form4_1767656950.xml · derivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,100

Underlying: Common Stock · 173,100 shares

Expires 2036-01-03

F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2027, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

Read SEC document
January 03, 2026 Filed Jan 5, 2026 23:49 UTC Denali Therapeutics Inc. DNLI · Entity 1735 GrantCommon Stock 57,700 $0.00 $0.00
Disclosure

SEC source: 0001724311-26-000001 · wk-form4_1767656950.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,046

F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2027 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

F2 · balance_after: Includes 141,100 Unvested RSUs.

Read SEC document
August 12, 2025 Filed Aug 15, 2025 00:33 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,937 $13.58 $39,884.46
Disclosure

SEC source: 0001724311-25-000011 · wk-form4_1755218026.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 242,346

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $13.35 to $13.58 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · balance_after: Includes 128,405 Unvested RSUs.

F4 · balance_after: Includes 975 shares acquired under the ESPP Purchase on June 2, 2025.

Read SEC document
January 07, 2025 Filed Jan 9, 2025 01:25 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,907 $20.81 $60,494.67
Disclosure

SEC source: 0001714899-25-000050 · wk-form4_1736385937.xml · nonDerivative · entry 2

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 244,308

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F3 · balance_after: Includes 134,030 Unvested RSUs.

Read SEC document
January 06, 2025 Filed Jan 9, 2025 01:25 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 12,255 $20.22 $247,796.10
Disclosure

SEC source: 0001714899-25-000050 · wk-form4_1736385937.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 247,215

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.91 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · balance_after: Includes 134,030 Unvested RSUs.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 23:57 UTC Denali Therapeutics Inc. DNLI · Entity 1735 GrantStock Option (right to buy) · Derivative 162,540 $0.00 Strike: $21.26 $0.00
Disclosure

SEC source: 0001714899-25-000027 · wk-form4_1736294268.xml · derivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,540

Underlying: Common Stock · 162,540 shares

Expires 2035-01-02

F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2026, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date

Read SEC document
January 03, 2025 Filed Jan 7, 2025 23:57 UTC Denali Therapeutics Inc. DNLI · Entity 1735 GrantCommon Stock 54,180 $0.00 $0.00
Disclosure

SEC source: 0001714899-25-000027 · wk-form4_1736294268.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 259,470

F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2026 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

F2 · balance_after: Includes 141,530 Unvested RSUs.

Read SEC document
December 27, 2024 Filed Dec 31, 2024 21:18 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 6,708 $0.00 Strike: $5.28 $0.00
Disclosure

SEC source: 0001714899-24-000236 · wk-form4_1735679885.xml · derivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,671

Underlying: Common Stock · 6,708 shares

Expires 2027-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.

Read SEC document
December 27, 2024 Filed Dec 31, 2024 21:18 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionCommon Stock 6,708 $5.28 $35,418.24
Disclosure

SEC source: 0001714899-24-000236 · wk-form4_1735679885.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,290

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 118,810 Unvested RSUs.

Read SEC document
November 22, 2024 Filed Nov 26, 2024 22:19 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 20,516 $0.00 Strike: $0.68 $0.00
Disclosure

SEC source: 0001714899-24-000234 · wk-form4_1732659560.xml · derivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,562

Underlying: Common Stock · 20,516 shares

Expires 2025-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.

Read SEC document
November 22, 2024 Filed Nov 26, 2024 22:19 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionCommon Stock 20,516 $0.68 $13,950.88
Disclosure

SEC source: 0001714899-24-000234 · wk-form4_1732659560.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,582

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: Includes 118,810 Unvested RSUs.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:44 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 15,558 $0.00 Strike: $5.28 $0.00
Disclosure

SEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · derivative · entry 6

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,379

Underlying: Common Stock · 15,558 shares

Expires 2027-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:44 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 300 $31.29 $9,387.00
Disclosure

SEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · nonDerivative · entry 4

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,066

F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.

F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.27 to $31.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F1 · balance_after: Includes 118,810 Unvested RSUs.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:44 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,925 $30.72 $89,856.00
Disclosure

SEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · nonDerivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,366

F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.

F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.21 to $31.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F1 · balance_after: Includes 118,810 Unvested RSUs.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:44 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 12,333 $29.68 $366,043.44
Disclosure

SEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · nonDerivative · entry 2

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 181,291

F2 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.

F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.21 to $30.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F1 · balance_after: Includes 118,810 Unvested RSUs.

Read SEC document
November 07, 2024 Filed Nov 12, 2024 21:44 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionCommon Stock 15,558 $5.28 $82,146.24
Disclosure

SEC source: 0001714899-24-000218 · wk-form4_1731447884.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 193,624

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 118,810 Unvested RSUs.

Read SEC document
August 21, 2024 Filed Aug 22, 2024 20:14 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,547 $24.78 $63,114.66
Disclosure

SEC source: 0001714899-24-000195 · wk-form4_1724357674.xml · nonDerivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,066

F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.

F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.19 to $25.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F2 · balance_after: Includes 118,810 Unvested RSUs.

Read SEC document
August 20, 2024 Filed Aug 22, 2024 20:14 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 3,353 $23.54 $78,929.62
Disclosure

SEC source: 0001714899-24-000195 · wk-form4_1724357674.xml · nonDerivative · entry 2

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,613

F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.

F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.38 to $23.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F2 · balance_after: Includes 118,810 Unvested RSUs.

Read SEC document
August 20, 2024 Filed Aug 22, 2024 20:14 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,453 $23.79 $58,356.87
Disclosure

SEC source: 0001714899-24-000195 · wk-form4_1724357674.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,966

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F2 · balance_after: Includes 118,810 Unvested RSUs.

Read SEC document
August 13, 2024 Filed Aug 15, 2024 20:10 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,272 $22.89 $52,006.08
Disclosure

SEC source: 0001714899-24-000177 · wk-form4_1723752595.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,419

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F2 · balance_after: Includes 123,810 RSUs.

F3 · balance_after: Includes 1,350 shares acquired under the ESPP Purchase on May 31, 2024.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 02:14 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 20,128 $17.66 $355,460.48
Disclosure

SEC source: 0001714899-24-000059 · wk-form4_1708049627.xml · nonDerivative · entry 2

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 187,341

F4 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.

F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · balance_after: Includes 129,435 RSUs.

Read SEC document
February 13, 2024 Filed Feb 16, 2024 02:14 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,716 $17.29 $46,959.64
Disclosure

SEC source: 0001714899-24-000059 · wk-form4_1708049627.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,469

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $17.08 to $17.30 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · balance_after: Includes 129,435 RSUs.

Read SEC document
February 08, 2024 Filed Feb 12, 2024 21:48 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 50,000 $0.00 Strike: $0.68 $0.00
Disclosure

SEC source: 0001714899-24-000042 · wk-form4_1707774481.xml · derivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,078

Underlying: Common Stock · 50,000 shares

Expires 2025-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.

Read SEC document
February 08, 2024 Filed Feb 12, 2024 21:48 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionCommon Stock 50,000 $0.68 $34,000.00
Disclosure

SEC source: 0001714899-24-000042 · wk-form4_1707774481.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,185

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 136,721 RSUs.

F2 · balance_after: Reflects 15,558 shares previously disclosed as held indirectly; but have been determined to be held directly.

Read SEC document
January 05, 2024 Filed Jan 10, 2024 00:34 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 9,972 $19.43 $193,755.96
Disclosure

SEC source: 0001714899-24-000036 · wk-form4_1704846835.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 539,307

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.36 to $19.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 25,530 RSUs held by the Reporting Person.

F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
January 03, 2024 Filed Jan 5, 2024 22:57 UTC Denali Therapeutics Inc. DNLI · Entity 1735 GrantStock Option (right to buy) · Derivative 161,160 $0.00 Strike: $20.33 $0.00
Disclosure

SEC source: 0001714899-24-000010 · wk-form4_1704495454.xml · derivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,160

Underlying: Common Stock · 161,160 shares

Expires 2034-01-02

F5 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 3, 2025, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

Read SEC document
January 03, 2024 Filed Jan 5, 2024 22:57 UTC Denali Therapeutics Inc. DNLI · Entity 1735 GrantCommon Stock 53,720 $0.00 $0.00
Disclosure

SEC source: 0001714899-24-000010 · wk-form4_1704495454.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,157

F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2025 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

F2 · balance_after: Includes 136,721 RSU's as of January 4, 2024.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 21:36 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,522 $23.17 $58,434.74
Disclosure

SEC source: 0001714899-23-000137 · wk-form4_1692999400.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 518,989

F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.87 to $23.36 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
August 21, 2023 Filed Aug 23, 2023 20:33 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,478 $22.59 $55,978.02
Disclosure

SEC source: 0001714899-23-000134 · wk-form4_1692822802.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 521,511

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.49 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 5,000 RSUs held by the Reporting Person.

F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
August 14, 2023 Filed Aug 16, 2023 22:19 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,772 $23.67 $65,613.24
Disclosure

SEC source: 0001714899-23-000124 · wk-form4_1692224345.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 518,989

F1 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.58 to $23.80 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
August 10, 2023 Filed Aug 14, 2023 21:11 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 2,853 $24.18 $68,985.54
Disclosure

SEC source: 0001714899-23-000121 · wk-form4_1692047483.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 521,761

F1 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F2 · price: . The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.99 to $24.35 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 5,625 RSUs held by the Reporting Person.

F4 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
July 18, 2023 Filed Jul 19, 2023 21:10 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 9,702 $30.01 $291,157.02
Disclosure

SEC source: 0001714899-23-000109 · wk-form4_1689801007.xml · nonDerivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 518,989

F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.04 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
July 17, 2023 Filed Jul 19, 2023 21:10 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $5.28 $0.00
Disclosure

SEC source: 0001714899-23-000109 · wk-form4_1689801007.xml · derivative · entry 5

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,937

Underlying: Common Stock · 10,000 shares

Expires 2027-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.

Read SEC document
July 17, 2023 Filed Jul 19, 2023 21:10 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 10,000 $29.60 $296,000.00
Disclosure

SEC source: 0001714899-23-000109 · wk-form4_1689801007.xml · nonDerivative · entry 2

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 528,691

F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.33 to $29.94 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
July 17, 2023 Filed Jul 19, 2023 21:10 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionCommon Stock 10,000 $5.28 $52,800.00
Disclosure

SEC source: 0001714899-23-000109 · wk-form4_1689801007.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 538,691

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Exercised shares were issued to the Schuth Family Trust.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
May 15, 2023 Filed May 17, 2023 20:56 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $5.28 $0.00
Disclosure

SEC source: 0001714899-23-000076 · wf-form4_168435700588836.xml · derivative · entry 5

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,937

Underlying: Common Stock · 10,000 shares

Expires 2027-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.

Read SEC document
May 15, 2023 Filed May 17, 2023 20:56 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 800 $29.23 $23,384.00
Disclosure

SEC source: 0001714899-23-000076 · wf-form4_168435700588836.xml · nonDerivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 528,691

F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.20 to $29.25 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
May 15, 2023 Filed May 17, 2023 20:56 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 9,200 $28.55 $262,660.00
Disclosure

SEC source: 0001714899-23-000076 · wf-form4_168435700588836.xml · nonDerivative · entry 2

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 529,491

F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.15 to $29.07 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
May 15, 2023 Filed May 17, 2023 20:56 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionCommon Stock 10,000 $5.28 $52,800.00
Disclosure

SEC source: 0001714899-23-000076 · wf-form4_168435700588836.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 538,691

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Exercised shares were issued to the Schuth Family Trust.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
April 13, 2023 Filed Apr 14, 2023 22:27 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 4,898 $0.00 Strike: $5.28 $0.00
Disclosure

SEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · derivative · entry 7

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,937

Underlying: Common Stock · 4,898 shares

Expires 2027-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.

Read SEC document
April 13, 2023 Filed Apr 14, 2023 22:27 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 4,898 $25.04 $122,645.92
Disclosure

SEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · nonDerivative · entry 4

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 528,691

F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
April 13, 2023 Filed Apr 14, 2023 22:27 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionCommon Stock 4,898 $5.28 $25,861.44
Disclosure

SEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · nonDerivative · entry 3

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 533,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Exercised shares were issued to the Schuth Family Trust.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 22:27 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 5,102 $0.00 Strike: $5.28 $0.00
Disclosure

SEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · derivative · entry 6

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,835

Underlying: Common Stock · 5,102 shares

Expires 2027-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 22:27 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 5,102 $25.04 $127,754.08
Disclosure

SEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · nonDerivative · entry 2

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 528,691

F3 · kind: The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.

F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
April 12, 2023 Filed Apr 14, 2023 22:27 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionCommon Stock 5,102 $5.28 $26,938.56
Disclosure

SEC source: 0001714899-23-000055 · wf-form4_168151121787982.xml · nonDerivative · entry 1

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 533,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Exercised shares were issued to the Schuth Family Trust.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:01 UTC Denali Therapeutics Inc. DNLI · Entity 1735 Exercise / conversionStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $0.68 $0.00
Disclosure

SEC source: 0001714899-23-000030 · wf-form4_167650569228111.xml · derivative · entry 4

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,078

Underlying: Common Stock · 25,000 shares

Expires 2025-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:01 UTC Denali Therapeutics Inc. DNLI · Entity 1735 SaleCommon Stock 3,497 $30.09 $105,224.73
Disclosure

SEC source: 0001714899-23-000030 · wf-form4_167650569228111.xml · nonDerivative · entry 2

Schuth Alexander O. · CIK 0001724311 · COFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 528,691

F3 · kind: Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.92 to $30.24 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5 · balance_after: Reflects the issuance of shares to The Schuth Family Trust U/A DTD 06/05/2017 in connection with the vesting of 7,286 RSUs held by the Reporting Person.

F2 · ownership.nature: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.